RxDoctor Payments Data

Cheyrl Phinney

Psychiatric/Mental Health · Bremerton, WANPI 1770804957

Payments from drug & device makers

$736in general payments, 2019–2025

Across 32 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$235
  • Johnson & Johnson$171
  • Lundbeck LLC$73
  • Neurocrine Biosciences, Inc.$71
  • Alkermes, Inc.$69
  • Sunovion Pharmaceuticals Inc.$58
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$736100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$736 in reported general payments places this provider in the 70th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Medicare billing

Part B allowed, 2024
$19,547
Medicare patients
63
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate50$153,085
IngrezzaValbenazine Tosylate11$83,189
AustedoDeutetrabenazine28$81,436
VraylarCariprazine Hcl21$28,836
GeodonZiprasidone Hcl22$26,863
Paliperidone ErPaliperidone108$8,032
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl33$5,414
Bupropion XlBupropion Hcl82$5,401
Clozapine74$3,225
Atomoxetine Hcl49$2,377
Prazosin Hcl209$1,993
Aripiprazole111$1,551
Quetiapine Fumarate156$1,519
Naltrexone Hcl68$1,418
Lurasidone Hcl54$1,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$171$153,08550 claims
Neurocrine Biosciences, Inc.Ingrezza$71$83,18911 claims
Teva Pharmaceuticals USA, Inc.Austedo$235$81,43628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 931 psychiatric/mental health providers in Washington.

Other psychiatric/mental health in Bremerton

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →